Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 2Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignant Solid Neoplasm 1

Interventions

Rituximab 32Cyclophosphamide 28Lenalidomide 19Prednisone 16Doxorubicin 16Vincristine 14Etoposide 11CT-P10 11Gemcitabine 9polatuzumab vedotin 8Oxaliplatin 7ibrutinib 6glofitamab 6fludarabine 6acalabrutinib 6Magnetic Resonance Spectroscopy 6Ifosfamide 6Carboplatin 6tafasitamab 5prednylidene 5pembrolizumab 5obinutuzumab 5deltacortene 5Specimen Handling 5R-CHOP protocol 5Nivolumab 5Biopsy 5venetoclax 4fludarabine phosphate 4selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Large B-Cell, Diffuse × Pharmacogenomic Variants × Clear all
NCT03479268 2026-04-27

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡